CardioComm Solutions, Inc
CardioComm Press Releases
News & Media


CardioComm Solutions Files New Patents for Automated Enabling of Over-The-Counter, Consumer, Bio-Monitoring Devices for Home Monitoring and Remote Diagnostic Interpretation.

The HeartCheck PEN ECG device is the first to utilize the patent pending SMART Monitoring technologies to enable/unlock a consumer medical devices to record, display, transmit and receive bio-signals and images.

TORONTO, ONTARIO -May 9, 2013. CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram (“ECG”) acquisition and management software solutions, today confirmed it has filed for U.S. and Canadian patents for use of their proprietary technologies in the automated, software enabled and server based unlocking of over-the-counter (“OTC”), consumer based, bio-monitoring devices. Under the U.S and Canadian patents, filed on May 6, 2013 and May 8, 2013 respectively, the Company will be permitted to apply the statement “Patent Pending SMART Monitoring Technologies” in its corporate materials until the application process has been completed.

The patent pending SMART Monitoring technologies are intended to enable, or unlock, personal health monitoring devices that display bio-sign wave forms and images and can be used for remote access interpretation. Until now such devices were available only under physician prescription.

In 2012, the Company announced their FDA clearance for the HeartCheck PEN ECG device, the first OTC consumer product capable of taking and displaying an ECG without the existence of a patient-physician relationship.  The clearance also included GEMS Home, a consumer heart rhythm management solution based on CardioComm Solutions’ proprietary Global ECG management and diagnostic (“GEMS”) and GlobalCardio software. Both GEMS and GlobalCardio have been in use globally under physician prescription for the diagnosis of ECG abnormalities for several years.  The solution involves a system of server-based validations where consumer and HeartCheck PEN device authentications permit ECG recordings to be taken from the HeartCheck PEN and viewed by a qualified healthcare professional or physician for diagnostic purposes.  The system, named SMART Monitoring, ensures the interpreted results are then returned to the registered consumer in compliance with all privacy and personal information protection regulations and laws. In May 2013, CardioComm Solutions announced completion of their infrastructure to ensure a 30 minute ECG interpretation service in support of their HeartCheck PEN sales and SMART Monitoring service.

The patent application scope covers more than ECG based technologies. “We are committed to capitalizing on our ongoing product development and software innovations. Accordingly, these patent applications are intended to extend to any bio-sign image management solution involving consumer based, home or remote access monitoring medical devices that are capable of recording, displaying and/or transmitting a biometric measure or image,” said Etienne Grima, Chief Executive Officer of the Company. “As we ready for news of our FDA clearance for GUAVA II, we are preparing for expansion of our SMART Monitoring technologies to include multiple bio-signs. Our GEMS and GlobalCardio software are cleared as a Class I and II medical products globally and contain drives to support devices from different manufacturers. With the addition of GUAVA II, which will have interpretation capabilities, we will maintain our device agnostic approach while expanding our reach into the growing disease prevention and home health care markets by adopting a disease agnostic SMART Monitoring solution,” added Grima.

The CardioComm Solutions’ patent applications have multiple claims involving the unlocking of an OTC product for bio-sign viewing and receipt of interpretive reports, under the control of a combination of device-unique and user-unique identifiers, cross matched on a robust and centralized monitoring server system. Through the use of these specific protocols confirming receipt and viewing of medical reports by physicians and consumers, the equivalent of a doctor-patient relationship is established. Once established, the monitoring server will update the device record of the bio-signal recorder to indicate that it is eligible for bio-sign signal viewing (unlocking).

The Company reports that results from the HeartCheck PEN, ECG-based SMART Monitoring solution and service are excellent.  Consumer feedback has shown this is a needed product. Customer testimonials can be reviewed on the CardioComm Solutions website at

 “We are looking forward to the 2013 calendar year as our ECG SMART Monitoring services continue to expand and as we plan for additional SMART Monitoring revenue generating opportunities from new consumer ECG recording devices and new biomarker measuring products such as pulse oxymetry, blood pressure and blood glucose,” said Simi Grosman, member of the Board of Directors for the Company. “These patent applications, and the ability to state Patent Pending in our literature, will allow CardioComm Solutions a less encumbered expansion into the available North American markets.”

About CardioComm Solutions
CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients.  Products are sold worldwide through a combination of an external distribution network and a North American-based sales team.  The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices.  CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.  

Etienne Grima, Chief Executive Officer

Forward-looking statements
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

  download pdf  
Investor Information

Investor Information

CardioComm Solutions stock is one of the most actively traded stocks on the TSX and TSX Venture Exchange

read article


"About 80 clinics in Ontario and across Canada have signed onto Cardiocomm's C4 arrythmia service since it was launched in 2009"

read article

" With a history of excellence in the Medical industry reaching back to the early 1990s, the medical software company, CardioComm Solutions, Inc. (CardioComm) continues to be a leader in ECG management technologies."
read article

"Hidden strengths thrive in the local tech market "

read article

Globe and Mail Investors -- Price Reports

read article

EKG CardioComm Solutions Inc

read article

Is a Tech Revival Happening on the TSX Venture Exchange?

read article

ECG test may signal heart attack risk in elderly

read article

Usefulness of Continuous Electrocardiographic Monitoring for Atrial Fibrillation

read article


Arrhythmia EKG Management | 12 Lead ECG Management | ECG Software | EKG Management | Web Based ECG | EKG Software